Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Novel activities of safe-in-human broad-spectrum antiviral agents

  • Aleksandr Ianevski
  • , Eva Zusinaite
  • , Suvi Kuivanen
  • , Mårten Strand
  • , Hilde Lysvand
  • , Mona Teppor
  • , Laura Kakkola
  • , Henrik Paavilainen
  • , Mira Laajala
  • , Hannimari Kallio-Kokko
  • , Miia Valkonen
  • , Anu Kantele
  • , Kaidi Telling
  • , Irja Lutsar
  • , Pille Letjuka
  • , Natalja Metelitsa
  • , Valentyn Oksenych
  • , Magnar Bjørås
  • , Svein Arne Nordbø
  • , Uga Dumpis
  • Astra Vitkauskiene, Christina Öhrmalm, Kåre Bondeson, Anders Bergqvist, Tero Aittokallio, Rebecca J. Cox, Magnus Evander, Veijo Hukkanen, Varpu Marjomaki, Ilkka Julkunen, Olli Vapalahti, Tanel Tenson, Andres Merits, Denis Kainov*
*Šī darba korespondējošais autors
  • Department of Clinical and Molecular Medicine
  • Norwegian University of Science and Technology
  • Institute of Technology
  • University of Tartu
  • Department of Virology
  • University of Helsinki
  • Department of Clinical Microbiology
  • Umeå University
  • Institute of Biomedicine
  • University of Turku
  • Department of Biological and Environmental Science
  • University of Jyväskylä
  • Department of Virology and Immunology
  • Helsinki University Central Hospital
  • Institute of Medical Microbiology
  • Narva
  • St. Olavs Hospital
  • Department of Medical Microbiology
  • Paula Stradina Clinical University Hospital
  • Department of Laboratory Medicine
  • Lithuanian University of Health Sciences
  • Department of Medical Sciences
  • Uppsala University
  • Institute for Molecular Medicine Finland
  • Department of Mathematics and Statistics
  • Department of Clinical Science
  • University of Bergen
  • Department of Veterinary Biosciences

Zinātniskās darbības rezultāts: Devums žurnālam › Zinātniskais raksts (žurnālā) › koleģiāli recenzēts

67 Atsauces (Scopus)

Kopsavilkums

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.

OriģinālvalodaAngļu
Lapas (no-līdz)174-182
Lapu skaits9
ŽurnālsAntiviral Research
Sējums154
DOIs
Publikācijas statussPublicēts - jūn. 2018
Ārēji publicētsJā

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Novel activities of safe-in-human broad-spectrum antiviral agents”. Kopā tie veido unikālu nospiedumu.

Citēt šo